Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 10/20 | 0.39 |
| ▸ | HRH1 | P35367 | 4/20 | 0.36 |
| ▸ | HTR2A | P28223 | 3/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | GSR | P00390 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27654798 | 0.98 | SLC7A5 (0.40) | SIGMAR1SLC7A5HRH1HTR2ASLC6A4 | |
| SCHEMBL6153356 | 0.94 | HRH1 (0.38) | SIGMAR1SLC7A5HRH1HTR2ASLC6A4 | |
| SCHEMBL3053696 | 0.85 | SLC6A4 (0.39) | HRH1HTR2ASLC6A4GSRTP53 | |
| SCHEMBL10531699 | 0.81 | LMNA (0.46) | CYP1A2 | |
| SCHEMBL1459570 | 0.80 | SLC7A5 (0.44) | SIGMAR1SLC7A5HTR2ASLC6A4 | |
| SCHEMBL27893880 | 0.79 | CHRNA7 (0.35) | SLC7A5SLC6A4 | |
| SCHEMBL8120558 | 0.79 | SIGMAR1 (0.59) | SIGMAR1HRH1HTR2A | |
| SCHEMBL7448877 | 0.78 | HTR2A (0.44) | SIGMAR1SLC7A5HTR2A | |
| SCHEMBL8048483 | 0.78 | HTR2A (0.44) | SIGMAR1SLC7A5HTR2A | |
| SCHEMBL9168419 | 0.78 | HTR2A (0.44) | SIGMAR1SLC7A5HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269291-A1 | Chemical Compounds | GLAXOSMITHKLINE LLC | 2008-10-30 | — | — | US | disclosed |
| EP-1948187-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007062318-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269291-A1 | Chemical Compounds | IDO2, IKBKG, NFKBIA | SIGMAR1 2248/4885SLC7A5 4301/4885HRH1 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.